艾德生物：股东的减持行为系其根据自身资金需求作出的独立决策

Core Viewpoint - The shareholder's reduction in holdings is an independent decision based on personal financial needs, and the company will adhere to regulatory disclosure obligations [1] Group 1: Company Strategy - The management is focused on strengthening the core competitiveness of its main business through increased R&D investment and deepening domestic market layout [1] - The company is accelerating its international expansion process and expanding strategic cooperation with pharmaceutical companies to drive sustainable and high-quality profit growth [1] - Continuous improvement in communication with the capital market is a priority for the company [1]